Amyotrophic Lateral Sclerosis.

  title={Amyotrophic Lateral Sclerosis.},
  author={Robert H. Brown and Ammar Al-Chalabi},
  journal={The New England journal of medicine},
  volume={377 2},
From the Department of Neurology, University of Massachusetts Medical School, Worcester (R.H.B.); and the Maurice Wohl Clinical Neuroscience Institute, Department of Basic and Clinical Neuroscience, King’s College London, London (A.A.-C.). Address reprint requests to Dr. Brown at the Department of Neurology, University of Massachusetts Medical School, 55 Lake Ave. N., Worcester, MA 01655, or at robert . brown@ umassmed . edu. 

Figures and Tables from this paper

Neuroprotection in Amyotrophic Lateral Sclerosis

  • K. Jain
  • Psychology, Medicine
    Springer Protocols Handbooks
  • 2019
Amyotrophic lateral sclerosis (ALS) is a progressive, devastating syndrome that affects both upper and motor neurons. It results in limbs and facial motor weakness, atrophy, spasticity, and death. It

Amyotrophic Lateral Sclerosis and Motor Neuron Disorders

The urologic care of patients with motor neuron disorders requires a thoughtful and comprehensive approach as these patients may have contraindications to traditional non-invasive medical therapy and may also have significant perioperative risk factors.

Psychiatric Symptoms in Amyotrophic Lateral Sclerosis: Beyond a Motor Neuron Disorder

This review aims at identifying the most common psychiatric alterations related to ALS and its prognosis, looking at a common genetic background and shared structural brain pathology.

Respiratory Failure in Amyotrophic Lateral Sclerosis

Massive Incidental Pneumoperitoneum in an Amyotrophic Lateral Sclerosis Patient

A 61-year-old male patient diagnosed with amyotrophic lateral sclerosis, who presented to the ER with worsening shortness of breath, several hours following elective percutaneous endoscopic gastrostomy (PEG) tube placement, was diagnosed with massive pneumoperitoneum.

Diagnostic Challenge and Neuromuscular Junction Contribution to ALS Pathogenesis

A combination of further research on the NMJ parameters that are specific for this disease and laboratory tests are crucial for the early determination of specific changes in the muscle, as well as in motor neuron and the prediction of ALS progression.

These violent repeats have violent extends

There is currently no cure for ALS and only 2 drugs have been approved, but these only offer limited benefit and more effective therapeutic strategies are desperately needed.

The genetic architecture of ALS




C9ORF72, implicated in amytrophic lateral sclerosis and frontotemporal dementia, regulates endosomal trafficking

This paper aims to demonstrate the efforts towards in-situ applicability of EMT in the context of Dementia Research and Education.

Amyotrophic Lateral Sclerosis Overview

The clinical characteristics of ALS are described and an evaluation strategy to identify the genetic cause of ALS in a proband is provided to provide a high-level view of management of ALS.

The changing scene of amyotrophic lateral sclerosis

New findings in ALS research are summarized, what they have taught us about this disease are discussed and issues that are still outstanding are examined.

The epidemiology and treatment of ALS: Focus on the heterogeneity of the disease and critical appraisal of therapeutic trials

  • E. BeghiA. Chiò S. Zoccolella
  • Medicine, Psychology
    Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases
  • 2011
Abstract Effective treatments for amyotrophic lateral sclerosis (ALS) have remained elusive. Only riluzole, a drug thought to affect glutamate metabolism, improves survival albeit to modest extent.

Amyotrophic lateral sclerosis.

Tremendous progress has been made in the field of ALS based on recent neuropathological and genetic discoveries and the role of metabolism and nutrition in the pathogenesis of the disease is debated and may potentially serve as a future therapeutic target.

State of play in amyotrophic lateral sclerosis genetics

Current literature of the major genes underlying ALS, SOD1, TARDBP, FUS, OPTN, VCP, UBQLN2, C9ORF72 and PFN1 are summarized and how each new genetic discovery is broadening the phenotype associated with the clinical entity the authors know as ALS is outlined.

ALS: Recent Developments from Genetics Studies

It is interesting to note that as the number of ALS genes grows, many of the proteins they encode are in shared intracellular processes.

The epidemiology of ALS: a conspiracy of genes, environment and time

The relationship between genetic and environmental risk factors is examined, and a disease model in which ALS is considered to be the result of environmental risks and time acting on a pre-existing genetic load is proposed, followed by an automatic, self-perpetuating decline to death.

Emerging mechanisms of molecular pathology in ALS.

Investigation of ALS genes have delineated pathogenic roles for perturbations in protein stability and degradation, altered homeostasis of critical RNA- and DNA-binding proteins, impaired cytoskeleton function, and non-neuronal cells as modifiers of the ALS phenotype.